Dolutegravir, Emtricitabine & Alafenamide tablets (SPEGRA)
Dolutegravir, Emtricitabine & Tenofovir Alafenamide Tablets (SPEGRA) are an advanced combination antiviral medicine designed for the management of Human Immunodeficiency Virus (HIV) infection. This formulation contains three active components that work together to reduce viral replication and support immune system health. SPEGRA combines an integrase inhibitor with nucleoside reverse transcriptase inhibitors to provide comprehensive antiretroviral activity. It is prescribed by healthcare professionals as part of a complete HIV treatment regimen. The medicine should be taken according to medical guidance to achieve optimal therapeutic outcomes and maintain consistent viral control.
Description
Dolutegravir, Emtricitabine & Tenofovir Alafenamide Tablets (SPEGRA) provide a comprehensive antiretroviral treatment approach for managing HIV-1 infection. This advanced combination medicine contains three active components that work together to control viral activity and support immune system function.
SPEGRA combines Dolutegravir, an integrase strand transfer inhibitor, with Emtricitabine and Tenofovir Alafenamide, which belong to the nucleoside reverse transcriptase inhibitor group. These active ingredients target different stages of the HIV replication cycle. Dolutegravir blocks the integration of viral genetic material into human cells, while Emtricitabine and Tenofovir Alafenamide interfere with reverse transcriptase activity to reduce the formation of new viral particles.
The formulation helps maintain effective viral suppression when patients follow the prescribed treatment schedule consistently. Regular use under medical supervision supports long-term HIV management and helps improve treatment outcomes. Patients should take this medicine exactly as recommended by their healthcare provider and should not adjust the dose or discontinue therapy without medical advice.
This combination tablet offers the convenience of multiple active ingredients in a single dosage form, helping patients follow their daily treatment routine more effectively. Doctors may recommend monitoring through regular health assessments and laboratory tests to evaluate treatment response and overall health status.
SPEGRA is designed for individuals requiring combination antiretroviral therapy and should only be used under professional medical guidance. Maintaining adherence, following a healthy lifestyle, and attending regular medical consultations play an important role in successful HIV management.
With its targeted mechanism of action and multi-drug composition, Dolutegravir, Emtricitabine & Tenofovir Alafenamide Tablets represent an important option in modern HIV care by helping healthcare providers achieve better control of viral replication and support patient wellness.
- Product Name: SPEGRA Tablets
- Active Ingredients: Dolutegravir, Emtricitabine & Tenofovir Alafenamide
- Medicine Type: Antiretroviral Combination Therapy
- Therapeutic Category: HIV Antiviral Medicine
- Drug Class: Integrase Strand Transfer Inhibitor (INSTI) + Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Primary Use: Management of HIV-1 infection
- Dosage Form: Oral Tablets
- Administration: As directed by a qualified healthcare professional
- Storage: Store as per manufacturer’s instructions
- Prescription Status: Prescription medicine
